Market Overview

Pfizer Separates Consumer Health Care Unit

Share:
Pfizer Separates Consumer Health Care Unit
Related PFE
The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
Midterms And The Stock Market: Potential Winners, Losers From The Coming Election
Ibrance + Faslodex extends survival in late-stage breast cancer study (Seeking Alpha)

After scrutiny from The White House, Pfizer Inc. (NYSE: PFE) announced new plans to split its existing two business units into three, further separating its consumer health care business.

What Happened

On Monday, President Donald Trump attacked the pharmaceutical giant on drug pricing, tweeting that Pfizer and others should be "ashamed." 

After Trump’s conversation with both U.S. Department of Health and Human Services Secretary Alex Azar and Pfizer CEO Ian Read, Pfizer reported that “prices would be deferred to levels seen 10 days ago as soon as technically possible, and the prices will remain in effect until the earlier of when the president’s blueprint goes into effect or the end of the year — whichever is sooner.”

The idea was "to give the president an opportunity to work on his blueprint to strengthen the health care system and provide more access for patients," according to Pfizer.

Soon after this, the pharma company announced new business plans.

Why It’s Important

Pfizer is now slated for separation into three units: Innovative Medicines, Established Medicines and Consumer Healthcare.

"This design gives us a sharper focus on diverse patients in diverse markets," Chief Operating Officer Albert Bourla said in a statement.

CEO Ian Read said in a statement that Pfizer expects a "higher and more sustained" revenue growth profile after 2020, and the new corporate structure will better position the individual businesses to achieve their potential.

What’s Next

The separation of business units is effective at the beginning of fiscal 2019, according to Pfizer. The company's stock was trading down 0.43 percent at $37.27 at time of publication.

Related Links: 

Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares

A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Posted-In: Donald Trump ReutersNews Health Care General Best of Benzinga

 

Related Articles (PFE)

View Comments and Join the Discussion!

38 Stocks Moving In Wednesday's Mid-Day Session

Jason Picks The Best Deals For July 11: $150 Off A Honda Portable Generator, Waterproof Binoculars And More